← feed

Is NCT03145948 results overdue?

Yes — results are overdue. Primary completion was 2017-08-16; the FDAAA-801 reporting deadline (2018-08-16) passed 2866 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

NCT IDNCT03145948 ↗
SponsorAbbVie (INDUSTRY)
Public issuerAbbVie Inc. — ABBV (CIK 0001551152) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusTERMINATED
Primary completion2017-08-16 (ACTUAL)
Reporting deadline2018-08-16 (completion + 365d)
Days overdue2866
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 7adccadfb12c921a… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03145948. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →